馬斯克旗下Neuralink英國啓動臨牀試驗 測試大腦晶片控制電腦
特斯拉(TSLA.US)創辦人馬斯克旗下大腦植入公司Neuralink正在英國啓動一項臨牀試驗,以進一步測試大腦植入晶片的病患者控制電腦和其他電子設備的能力。
根據研究地點之一倫敦大學學院醫院發佈的公告,該試驗將對多達七名患有嚴重神經系統疾病、無法使用電子設備的患者評估該大腦晶片的安全性和功能性。
迄今至少有9人在臨牀試驗中接受該公司植入晶片,該試驗也在美國、加拿大和阿聯酋進行。Neuralink也正研發其他植入晶片,以幫助盲人重見光明或治療柏金遜症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.